首页> 外文期刊>Health policy and planning >Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
【24h】

Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries

机译:抗疟疾的价格和加价:来自六个疟疾流行国家的国家代表性研究的证据

获取原文
获取原文并翻译 | 示例
           

摘要

The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin therapies (nATs). This study seeks to better understand consumer antimalarial prices by documenting and exploring the pricing behaviour of retailers and wholesalers. Using data collected in 2009-10, we present survey estimates of antimalarial retail prices, and wholesale- and retail-level price mark-ups from six countries (Benin, Cambodia, the Democratic Republic of Congo, Nigeria, Uganda and Zambia), along with qualitative findings on factors affecting pricing decisions. Retail prices were lowest for nATs, followed by ACTs and artemisinin monotherapies (AMTs). Retailers applied the highest percentage mark-ups on nATs (range: 40% in Nigeria to 100% in Cambodia and Zambia), whereas mark-ups on ACTs (range: 22% in Nigeria to 71% in Zambia) and AMTs (range: 22% in Nigeria to 50% in Uganda) were similar in magnitude, but lower than those applied to nATs. Wholesale mark-ups were generally lower than those at retail level, and were similar across antimalarial categories in most countries. When setting prices wholesalers and retailers commonly considered supplier prices, prevailing market prices, product availability, product characteristics and the costs related to transporting goods, staff salaries and maintaining a property. Price discounts were regularly used to encourage sales and were sometimes used by wholesalers to reward long-term customers. Pricing constraints existed only in Benin where wholesaler and retailer mark-ups are regulated; however, unlicensed drug vendors based in open-air markets did not adhere to the pricing regime. These findings indicate that mark-ups on antimalarials are reasonable. Therefore, improving ACT affordability would be most readily achieved by interventions that reduce commodity prices for retailers, such as ACT subsidies, pooled purchasing mechanisms and cost-effective strategies to increase the distribution coverage area of wholesalers.
机译:私营营利部门是治疗疟疾的重要来源。但是,私人患者面对简单的疟疾青蒿素联合疗法(ACT)的推荐治疗方法面临高昂价格,这使他们更有可能接受更便宜,效果更差的非青蒿素疗法(nAT)。本研究旨在通过记录和探索零售商和批发商的定价行为,以更好地了解消费者的抗疟价格。使用2009-10年度收集的数据,我们提供了六个国家(贝宁,柬埔寨,刚果民主共和国,尼日利亚,乌干达和赞比亚)的抗疟药零售价格以及批发和零售价的调查估计值,以及对影响定价决策的因素进行定性研究。 nAT的零售价格最低,其次是ACT和青蒿素单一疗法(AMT)。零售商对nAT的加价幅度最高(范围:尼日利亚为40%,柬埔寨和赞比亚为100%),而ACT的加价幅度(范围为:尼日利亚的22%至赞比亚的71%)和AMT(范围:尼日利亚的比例为22%,乌干达的比例为50%),但幅度低于适用于nAT的幅度。批发加价通常低于零售价,在大多数国家中,抗疟药类别的批发价都相似。在确定价格时,批发商和零售商通常考虑供应商价格,现行市场价格,产品可用性,产品特性以及与运输货物,员工工资和维护财产有关的成本。经常使用价格折扣来鼓励销售,批发商有时会使用价格折扣来奖励长期客户。价格限制仅存在于贝宁,那里对批发商和零售商的加价进行了规范;但是,露天市场的无牌药品销售商并未遵守定价制度。这些发现表明,抗疟疾的加价是合理的。因此,通过降低零售商商品价格的干预措施,例如ACT补贴,集中购买机制和具有成本效益的策略来增加批发商的分销覆盖面,将最容易实现提高ACT负担能力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号